ClinicalTrials.gg
RecruitingNCT06936189Updated May 16, 2025

Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)(Extended Follow-Up)

An observational study in Carotid Artery Stenosis, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
204
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Carotid Stenosis with a site in China — 33 open to participants now, 37 under way, 1 of them phase 3. Carotid Stenosis · China.

Planned enrollment
14th of 34
204 · median 200
Started
2025
with 7 others
Observational
34 of 71
19 open now
Primary completion
2027-12
later than 25 of 36 live
Registered
55th of 71
by date
Lead sponsor
2 of 71
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Among the 71 studies in Carotid Stenosis with a site in China, this one is the 14th largest by planned enrollment of the 34 observational ones that give a count, is one of 8 that started in 2025, is one of 34 observational ones, reaches primary completion later than 25 of the 36 other live ones, and was the 55th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

33 of the 71 studies in Carotid Stenosis with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carotid Stenosis with a site in China, or all of them as a file.
02

Study summary

Purpose: To assess the long-term safety and efficacy of the intravascular lithotripsy system for pre-treatment of calcified carotid artery stenosis.

Design: Prospective, multicenter, single-arm study with an extended follow-up period.

Sample Size: 204 participants (based on the final number of cases enrolled in the registration trial).

Endpoints:

Primary: Surgical success rate (residual stenosis \<30% after stenting). Secondary: Target lesion re-narrowing rate, target lesion revascularization rate, MAE rate, ipsilateral stroke rate, and MACCE rate at 3 and 6 months postoperatively.

Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively.

Inclusion criteria:

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Ethics and Consent: The trial will be conducted in accordance with the Helsinki Declaration and Chinese regulations. Informed consent will be obtained from all participants or their legal guardians.

Sponsor: Shanghai Lanfan Boyuan Medical Technology Co., Ltd. Principal Investigator: Professor Huo Xiaochuan, Beijing Anzhen Hospital.

Read the detailed description

### Detailed Description

This clinical trial evaluates the safety and long-term efficacy of a disposable neurovascular intravascular lithotripsy (IVL) catheter and intravascular lithotripsy treatment device for pre-treatment of calcified lesions in the extracranial segment of the carotid artery. The study is designed as a prospective, multicenter, single-arm trial (extended follow-up period).

#### Study Population:

All patients participating in this extended follow-up period are sourced from the registered clinical trial.(The registered clinical trial:Participants aged 18-80 years with symptomatic (≥50%) or asymptomatic (≥70%) calcified carotid artery stenosis confirmed by CT angiography (CTA) and digital subtraction angiography (DSA) are eligible. Patients who have failed conventional balloon dilation and are planned for carotid artery stenting (CAS) will be included.)

#### Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively. Assessments will include clinical evaluations, imaging studies (CT angiography or carotid ultrasound), and recording of adverse events.

  • Endpoints:

    • **Primary Endpoint**: Surgical success rate defined as residual stenosis \<30% after stenting.
    • **Secondary Endpoints**: Target lesion re-narrowing rate, target lesion revascularization rate, MAE (major adverse events) rate, ipsilateral stroke rate, and MACCE (major adverse cardiovascular and cerebrovascular events) rate at 3 and 6 months postoperatively.
  • Ethical Considerations:

Informed consent will be obtained from all participants or their legal guardians. The study will be conducted in accordance with the Helsinki Declaration and local regulatory requirements.

03

Conditions studied

  • Carotid Artery Stenosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Exclusion criteria

Exclusion criteria:

none

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
204 participants (estimated)
Patient registry
No

Groups and cohorts

  • Calcified Carotid Artery Stenosis Treated with IVL and Carotid Artery Stenting (CAS)

    All patients participating in this extended follow-up period are sourced from the registered clinical trial.

06

What researchers measure

Primary outcomes

  1. Target lesion re-narrowing rate

    Proportion of patients with ≥50% diameter stenosis at the target lesion, assessed by imaging at 3 and 6 months.

    Time frame: at 3 months and 6 months postoperatively

Secondary outcomes

  1. Target lesion revascularization rate

    Incidence of repeat revascularization procedures at the treated lesion, evaluated at 3 and 6 months.

    Time frame: at 3 months and 6 months postoperatively

  2. MAE (Major Adverse Events) rate

    Rate of major adverse events (death, myocardial infarction, stroke) within 3 and 6 months.

    Time frame: at 3 months and 6 months postoperatively

  3. Ipsilateral stroke rate

    Incidence of stroke on the treated side, confirmed by clinical and imaging studies at 3 and 6 months.

    Time frame: at 3 months and 6 months postoperatively

  4. MACCE (Major Adverse Cardio-Cerebrovascular Events) rate

    Composite rate of death, stroke, myocardial infarction, and revascularization at 3 and 6 months.

    Time frame: at 3 months and 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 87 observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 104. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2025
First posted
Apr 20, 2025
StartActual
May 12, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06936189
Responsible party
Sponsor
First posted
Apr 20, 2025
Start date
May 12, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 16, 2025

Study contacts

Xiaochuan Huo
Contact
huoxiaochuan@126.com
010-64412431

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion